Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D MOLECULAR THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

05/20/2021 | 04:08pm EST

Item 5.07 Submission of Matters to a Vote of Security Holders.

4D Molecular Therapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting") on May 17, 2021 virtually via the internet. On March 26, 2021, the record date, there were 26,694,379 shares of the Company's common stock outstanding with each such share being entitled to one vote per share.

At the Annual Meeting, 16,717,561 shares of the Company's common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 6, 2021.


Proposal 1. The Company's stockholders elected by a majority of votes cast the
Class I director nominees below to the Company's Board of Directors to hold
office until the 2024 Annual Meeting of Stockholders or until their successors
are elected.



                                                          BROKER
                                                           NON-
NOMINEE                     FOR           WITHHELD         VOTES
David Kirn, M.D.          13,952,085       1,873,828       891,648
David Schaffer, Ph.D.     13,179,909       2,646,004       891,648



Proposal 2. The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.



    FOR          AGAINST      ABSTAIN
  16,698,132       18,996       433



                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about 4D MOLECULAR THERAPEUTICS, INC.
01/14BofA Securities Says IPO Performance Was Weak in 2021 But Fundamentals Remain Intact fo..
MT
01/114D MOLECULAR THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/104D Molecular Therapeutics' Treatment for Retinal Disorder Gets FDA Fast Track Designati..
MT
01/104D Molecular Therapeutics Gets Fast-Track Designation for Retinal Disease Treatment
DJ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
AQ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
CI
01/064D Molecular Says First Patient Dosed in Trial of 4D-150 Candidate to Treat Eye Disease
MT
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations